A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: SHR-1210 + Apatinib +Fluzoparib
Sponsor: Jiangsu HengRui Medicine Co., Ltd.